Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

TS03 Inc Trust Units TSTIF



GREY:TSTIF - Post by User

Post by investryon Feb 25, 2016 7:16am
114 Views
Post# 24593017

NR: Recruiting, Supplier Relationships and Improved Process

NR: Recruiting, Supplier Relationships and Improved Process

Qubec City, Qubec – February 25, 2016 – TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, reported an improved outlook for its production and operating capacity of STERIZONE® VP4 Sterilizers at its existing Qubec, Canada facility. 

As announced in December 2015, TSO3 set out to rapidly increase its ability to meet unprecedented demand for its STERIZONE® VP4 Sterilizer from its exclusive distribution partner, Getinge Infection Control AB, the world leader in infection control solutions. Since then, TSO3 has reviewed its recruiting, supplier relationships and process flows and confirms that the facility can support 200 units annually. The Company is further optimizing its process work flows and systems in the Qubec facility, and expects to be able to produce one sterilizer per day by the third fiscal quarter of 2016. 

TSO3’s production rates have increased significantly in each of the last three months to address demand, and the Company has already surpassed, to date, all previous production records in its history. The Company has hired and trained additional skilled assemblers and quality assurance personnel and is working with key suppliers to receive required components in the quantities and quality required, in a timely manner. 

“The Quebec facility is in the second phase of ramping manufacturing capacity to 200 units annually by mid-March,” said TSO3 Chief Operating Officer Harold Tessman. “We have improved our operations team, including the recruitment of several managers and technical professionals with solid backgrounds in the medical device industry. Our Tier 1 suppliers have been identified and are producing, and the Company has initiated an accelerated lean transformation of assembly operations.” 

R.M. (Ric) Rumble, TSO3’s president and CEO, commented: “The progress we have made in our assembly operations is on track with our plan and addresses a significant hurdle in our growth objectives. We look forward to providing further updates in the coming months on what is shaping up to be a record year.” 

While TSO3 believes current capacity will satisfy its production needs for the 2016 fiscal year, the Company is actively exploring additional locations and/or means to produce at greater volumes in 2017 and beyond. 

Link: https://www.tso3.com/en/news_events/article/148/

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse